TY - JOUR
T1 - Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients
AU - Bertazzoni, Paola
AU - Rabascio, Cristina
AU - Gigli, Federica
AU - Calabrese, Liliana
AU - Radice, Davide
AU - Calleri, Angelica
AU - Gregato, Giuliana
AU - Negri, Mara
AU - Liptrott, Sarah J.
AU - Bassi, Simona
AU - Nassi, Luca
AU - Sammassimo, Simona
AU - Laszlo, Daniele
AU - Preda, Lorenzo
AU - Pruneri, Giancarlo
AU - Orlando, Laura
AU - Martinelli, Giovanni
PY - 2010/8
Y1 - 2010/8
N2 - The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL). Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m
2 on day 1 and cladribine 0.1 mg/kg subcutaneously on days 26. The treatment was repeated every 4 weeks for a total of four cycles. Sixteen patients were pretreated. The overall response rate was 88 (50 complete remission and 38 partial remission). The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5 of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL.
AB - The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL). Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m
2 on day 1 and cladribine 0.1 mg/kg subcutaneously on days 26. The treatment was repeated every 4 weeks for a total of four cycles. Sixteen patients were pretreated. The overall response rate was 88 (50 complete remission and 38 partial remission). The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5 of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL.
KW - Chronic lymphocytic leukemia
KW - rituximab
KW - small lymphocytic lymphoma
KW - subcutaneous cladribine
UR - http://www.scopus.com/inward/record.url?scp=77955449996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955449996&partnerID=8YFLogxK
U2 - 10.3109/10428194.2010.495799
DO - 10.3109/10428194.2010.495799
M3 - Article
C2 - 20578816
AN - SCOPUS:77955449996
VL - 51
SP - 1485
EP - 1493
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 8
ER -